Trials / Terminated
TerminatedNCT00633997
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | 50 mg orally twice daily for 10 days (last dose morning of day 10) |
| DRUG | Vildagliptin |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-12-01
- First posted
- 2008-03-12
- Last updated
- 2020-12-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00633997. Inclusion in this directory is not an endorsement.